RECORD // Company

SELLAS Life Sciences Group, Inc.

Formerly: GALENA BIOPHARMA, INC.; Galena Biopharma, Inc.; RXI PHARMACEUTICALS CORP

Built 2026-11-21T16:00:17Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (8)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Sellas Life Sciences Group · Ctgov · exact name match to 'SELLAS Life Sciences Group, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SELLAS LIFE SCIENCES GROUP, INC. · Ny corps · same registered legal name as 'SELLAS Life Sciences Group, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001390478-26-000020

ItemValuePeriodFormFiledAccessionReport
Revenue$09 months ended 2026-09-3010-Q2026-11-120001390478-26-0000202026-11-21 16:00 UTCReport an error
Net income (loss)$-10,091,0003 months ended 2026-09-3010-Q2026-11-120001390478-26-0000202026-11-21 16:00 UTCReport an error
Cash and cash equivalents$134,711,000at 2026-09-3010-Q2026-11-120001390478-26-0000202026-11-21 16:00 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001390478
Ticker
SLS
CUSIP
81642T209
Record ID
sx:sec:0001390478

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-21 16:00 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-20SEC EDGAR company profile2026-11-21 16:00 UTCReport an error
State of incorporationDE2026-11-20SEC EDGAR company profile2026-11-21 16:00 UTCReport an error
Fiscal year end (MMDD)12312026-11-20SEC EDGAR company profile2026-11-21 16:00 UTCReport an error
Business address7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 100362026-11-20SEC EDGAR company profile2026-11-21 16:00 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-21 16:00 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-26,863,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 16:00 UTCReport an error
Total assets (at 2025-12-31)$78,345,0002025-12-3110-K, XBRL Assets2026-11-21 16:00 UTCReport an error
Stockholders' equity (at 2025-12-31)$70,871,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 16:00 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$71,793,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 16:00 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-28,389,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 16:00 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,001,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 16:00 UTCReport an error
Form D total offering amount (D filed 2024-03-29)$18,371,3362024-03-29D2026-11-21 16:00 UTCReport an error
Form D total amount sold (D filed 2024-03-29)$18,371,3362024-03-29D2026-11-21 16:00 UTCReport an error
Form D industry groupBiotechnology2024-03-29D2026-11-21 16:00 UTCReport an error
Form D revenue rangeDecline to Disclose2024-03-29D2026-11-21 16:00 UTCReport an error
Form D date of first sale2024-03-152024-03-29D2026-11-21 16:00 UTCReport an error
8-K Item 1.01 (filed 2026-11-20)Entry into a Material Definitive Agreement. On November 18, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering of 11,538,462 shares (the “Offering Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a price to public of $13.00 per share. In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 1,730,769 additional…2026-11-20SEC EDGAR 8-K 0001104659-26-130331 (text as filed, excerpt)2026-11-21 16:00 UTCReport an error
8-K Item 8.01 (filed 2026-11-20)Other Events. On November 18, 2026, the Company issued a press release announcing the pricing of the underwritten public offering, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.2026-11-20SEC EDGAR 8-K 0001104659-26-130331 (text as filed, excerpt)2026-11-21 16:00 UTCReport an error
8-K Item 7.01 (filed 2026-11-17)Regulation FD Disclosure On November 17, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) issued a press release (the “Press Release”) announcing positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (“GPS”), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (“AML”). A copy of the Press Release is attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of…2026-11-17SEC EDGAR 8-K 0001104659-26-128825 (text as filed, excerpt)2026-11-21 16:00 UTCReport an error
8-K Item 8.01 (filed 2026-11-17)Other Events. On November 17, 2026, the Company issued the Press Release announcing positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating GPS, an immunotherapeutic cancer vaccine, in patients with AML. The pivotal trial evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete remission (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation. The REGAL trial met its primary endpoint of overall survival (“OS”), with GPS demonstrating a statistically significant…2026-11-17SEC EDGAR 8-K 0001104659-26-128825 (text as filed, excerpt)2026-11-21 16:00 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-12)On November 12, 2026, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2026 and providing a corporate update. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The…2026-11-12SEC EDGAR 8-K 0001390478-26-000021 (text as filed, excerpt)2026-11-21 16:00 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-11)On August 11, 2026, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026 and providing a corporate update. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information…2026-08-11SEC EDGAR 8-K 0001390478-26-000013 (text as filed, excerpt)2026-11-21 16:00 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$222,437,6572026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error
Largest institutional holder #2 (13F as filed): STATE STREET CORP$191,829,1962026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$121,417,3102026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error
Largest institutional holder #4 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$72,107,0102026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error
Largest institutional holder #5 (13F as filed): Anson Funds Management LP$66,420,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$31,897,8212026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error
Largest institutional holder #7 (13F as filed): SUSQUEHANNA INTERNATIONAL GROUP, LLP$30,266,8122026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error
Largest institutional holder #8 (13F as filed): JONES FINANCIAL COMPANIES LLLP$28,553,5112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error
Largest institutional holder #9 (13F as filed): NORTHERN TRUST CORP$23,910,1382026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error
Largest institutional holder #10 (13F as filed): VANGUARD FIDUCIARY TRUST CO$19,707,0502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 16:00 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.